11,294 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by Guided Capital Wealth Management LLC

Guided Capital Wealth Management LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,294 shares of the medical research company's stock, valued at approximately $1,788,000. Natera makes up about 1.6% of Guided Capital Wealth Management LLC's portfolio, making the stock its 15th largest position.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Chartwell Investment Partners LLC raised its holdings in Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company's stock worth $5,243,000 after acquiring an additional 11,362 shares during the last quarter. Cerity Partners LLC grew its position in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock valued at $10,936,000 after buying an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Natera in the 3rd quarter worth $385,000. Everence Capital Management Inc. bought a new position in shares of Natera in the fourth quarter worth about $573,000. Finally, First Turn Management LLC purchased a new stake in shares of Natera in the third quarter worth $19,760,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

NTRA has been the topic of several research analyst reports. The Goldman Sachs Group boosted their target price on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Barclays began coverage on Natera in a research note on Thursday, January 23rd. They set an "overweight" rating and a $200.00 price target for the company. TD Cowen raised their price objective on Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Canaccord Genuity Group lifted their target price on Natera from $165.00 to $180.00 and gave the company a "buy" rating in a research note on Friday, January 3rd. Finally, Craig Hallum upped their price objective on shares of Natera from $121.00 to $157.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $165.88.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now directly owns 267,629 shares in the company, valued at approximately $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gail Boxer Marcus sold 9,682 shares of the company's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total value of $1,548,926.36. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at approximately $1,552,445.92. This trade represents a 49.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 305,454 shares of company stock valued at $51,290,625 over the last ninety days. Insiders own 7.60% of the company's stock.

Natera Price Performance

Shares of NASDAQ:NTRA traded up $2.66 during trading on Friday, reaching $173.39. 1,571,626 shares of the company's stock traded hands, compared to its average volume of 1,326,767. The firm has a market cap of $22.89 billion, a PE ratio of -98.52 and a beta of 1.66. The company has a 50-day simple moving average of $167.75 and a 200-day simple moving average of $143.14. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a fifty-two week low of $68.03 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.95) earnings per share. As a group, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.